Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
- PMID:15175436
- DOI: 10.1056/NEJMoa032709
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
Abstract
Background: The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting.
Methods: We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival.
Results: A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent).
Conclusions: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Copyright 2004 Massachusetts Medical Society
Comment in
- Two steps forward in the treatment of colorectal cancer.Mayer RJ.Mayer RJ.N Engl J Med. 2004 Jun 3;350(23):2406-8. doi: 10.1056/NEJMe048098.N Engl J Med. 2004.PMID:15175443No abstract available.
- Oxaliplatin in colon cancer.Mandalà M, Ferretti G, Barni S.Mandalà M, et al.N Engl J Med. 2004 Oct 14;351(16):1691-2; author reply 1691-2. doi: 10.1056/NEJM200410143511623.N Engl J Med. 2004.PMID:15483293No abstract available.
- Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.[No authors listed][No authors listed]Cancer Treat Rev. 2004 Dec;30(8):711-3. doi: 10.1016/j.ctrv.2004.09.002.Cancer Treat Rev. 2004.PMID:15541581No abstract available.
Similar articles
- Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.André T, et al.J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.J Clin Oncol. 2009.PMID:19451431Clinical Trial.
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.de Gramont A, et al.Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.Lancet Oncol. 2012.PMID:23168362Clinical Trial.
- Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.Kuebler JP, et al.J Clin Oncol. 2007 Jun 1;25(16):2198-204. doi: 10.1200/JCO.2006.08.2974. Epub 2007 Apr 30.J Clin Oncol. 2007.PMID:17470851Clinical Trial.
- Adjuvant therapy of colon cancer.Macdonald JS, Astrow AB.Macdonald JS, et al.Semin Oncol. 2001 Feb;28(1):30-40. doi: 10.1016/s0093-7754(01)90043-0.Semin Oncol. 2001.PMID:11254865Review.
- Adjuvant therapy in colon cancer: which treatment in 2005?Di Costanzo F, Doni L.Di Costanzo F, et al.Ann Oncol. 2005 May;16 Suppl 4:iv69-73. doi: 10.1093/annonc/mdi911.Ann Oncol. 2005.PMID:15923433Review.No abstract available.
Cited by
- Rac1 promotes the reprogramming of glucose metabolism and the growth of colon cancer cells through upregulating SOX9.Liang J, Liu Q, Xia L, Lin J, Oyang L, Tan S, Peng Q, Jiang X, Xu X, Wu N, Tang Y, Su M, Luo X, Yang Y, Liao Q, Zhou Y.Liang J, et al.Cancer Sci. 2023 Mar;114(3):822-836. doi: 10.1111/cas.15652. Epub 2022 Nov 29.Cancer Sci. 2023.PMID:36369902Free PMC article.
- Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY.Lu CY, et al.Br J Cancer. 2013 Mar 5;108(4):791-7. doi: 10.1038/bjc.2012.595. Epub 2013 Feb 19.Br J Cancer. 2013.PMID:23422758Free PMC article.
- The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.Azar I, Al Masalmeh N, Esfandiarifard S, Virk G, Kiwan W, Frank Shields A, Mehdi S, Philip PA.Azar I, et al.Cancer Med. 2021 May;10(9):2987-2995. doi: 10.1002/cam4.3757. Epub 2021 Apr 2.Cancer Med. 2021.PMID:33797856Free PMC article.
- Successful hybrid surgery for ileal conduit stomal varices following oxaliplatin-based chemotherapy in a patient with advanced colorectal cancer.Uehara H, Kawanaka H, Nakanoko T, Sugiyama M, Ota M, Mano Y, Sugimachi K, Morita M, Toh Y.Uehara H, et al.Surg Case Rep. 2020 Sep 29;6(1):236. doi: 10.1186/s40792-020-01021-6.Surg Case Rep. 2020.PMID:32990797Free PMC article.
- Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.Chen D, Wen X, Song YS, Rhee YY, Lee TH, Cho NY, Han SW, Kim TY, Kang GH.Chen D, et al.Clin Epigenetics. 2016 Apr 5;8:36. doi: 10.1186/s13148-016-0203-8. eCollection 2016.Clin Epigenetics. 2016.PMID:27051466Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources